Antibody effector mechanisms in myasthenia gravis—Pathogenesis at the neuromuscular junction-Reference-Cited by-同舟云学术

Antibody effector mechanisms in myasthenia gravis—Pathogenesis at the neuromuscular junction

Published:2010-04-12 Issue:5-6 Volume:43 Page:353-370
ISSN:0891-6934
Container-title:Autoimmunity
language:en
Short-container-title:Autoimmunity

Author:

Gomez Alejandro M.,Van Den Broeck Joost,Vrolix Kathleen,Janssen Sofie P.,Lemmens Marijke A. M.,Van Der Esch Eline,Duimel Hans,Frederik Peter,Molenaar Peter C.,Martínez-Martínez Pilar,De Baets Marc H.,Losen Mario

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.3109/08916930903555943

Reference154 articles.

1. Antibody to acetylcholine receptor in myasthenia gravis: Prevalence, clinical correlates, and diagnostic value

2. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies

3. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis

4. Inhibition of synapse assembly in mammalian muscle in vivo by RNA interference

5. Immunosuppressive therapies in myasthenia gravis

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circ_0076490 silencing inhibits MAPK1 expression to decrease the proliferation and increase apoptosis of Jurkat cells by regulating miR-144-3p in myasthenia gravis;Neurological Research;2024-08-29

2. Independent risk factors for in-hospital outcome of myasthenic crisis: a prospective cohort study;Therapeutic Advances in Neurological Disorders;2024-01

3. Delving into Molecular Pathways: Analyzing the Mechanisms of Action of Monoclonal Antibodies Integrated in IMGT/mAb-DB for Myasthenia Gravis;Vaccines;2023-11-26

4. In Search of a Function for the N6-Methyladenosine in Epitranscriptome, Autophagy and Neurodegenerative Diseases;Neurology International;2023-08-10

5. Detection of autoantibodies against the acetylcholine receptor, evaluation of commercially available methodologies: fixed Cell-Based Assay, Radioimmunoprecipitation Assay and Enzyme-Linked Immunosorbent Assay;2023-08-05